ProKidney (NASDAQ:PROK) Shares Gap Down to $4.12

ProKidney Corp. (NASDAQ:PROK - Get Free Report)'s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $4.12, but opened at $3.95. ProKidney shares last traded at $4.26, with a volume of 174,898 shares traded.

Analysts Set New Price Targets

Separately, Morgan Stanley assumed coverage on ProKidney in a research note on Thursday, March 7th. They issued an "equal weight" rating and a $3.00 price objective on the stock.

ProKidney Trading Down 4.9 %

The stock has a fifty day simple moving average of $1.96 and a two-hundred day simple moving average of $1.72. The company has a market cap of $899.01 million, a PE ratio of -6.70 and a beta of 0.78.

ProKidney (NASDAQ:PROK - Get Free Report) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.10. As a group, equities research analysts anticipate that ProKidney Corp. will post -0.61 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Darin J. Weber sold 84,103 shares of ProKidney stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $1.73, for a total transaction of $145,498.19. Following the completion of the sale, the senior vice president now directly owns 189,670 shares in the company, valued at approximately $328,129.10. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, SVP Darin J. Weber sold 84,103 shares of the firm's stock in a transaction on Friday, April 12th. The stock was sold at an average price of $1.73, for a total value of $145,498.19. Following the completion of the transaction, the senior vice president now owns 189,670 shares in the company, valued at $328,129.10. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Darin J. Weber sold 16,438 shares of ProKidney stock in a transaction on Monday, April 22nd. The stock was sold at an average price of $2.51, for a total value of $41,259.38. Following the transaction, the senior vice president now directly owns 155,194 shares of the company's stock, valued at approximately $389,536.94. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 118,879 shares of company stock valued at $232,392. Corporate insiders own 44.99% of the company's stock.

Institutional Trading of ProKidney

Large investors have recently modified their holdings of the business. SG Americas Securities LLC purchased a new stake in ProKidney in the 3rd quarter valued at approximately $78,000. Jump Financial LLC purchased a new stake in shares of ProKidney in the third quarter valued at $216,000. Federated Hermes Inc. increased its position in ProKidney by 10,984.7% during the 4th quarter. Federated Hermes Inc. now owns 113,286 shares of the company's stock worth $202,000 after purchasing an additional 112,264 shares in the last quarter. Finally, Zullo Investment Group Inc. acquired a new stake in shares of ProKidney during the 1st quarter worth about $32,000. 51.59% of the stock is currently owned by institutional investors and hedge funds.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.